Article

Most Opioid Prescriptions not Aligned with Treatment Guidelines

OARSI 2019:  Half of opioid prescriptions made today are not aligned with treatment guidelines.

(©DavidSmartShutterstock)

(©DavidSmartShutterstock)

Half of opioid prescriptions made today are not aligned with treatment guidelines, say researchers reporting this weekend in Toronto at the Osteoarthritis Research Society International (OARSI) World Congress on Osteoarthritis.

Jonas Bloch Thorlund of the University of Southern Denmark reported that “half of opioids dispensed to patients with a new knee or hip osteoarthritis diagnosis are inappropriate according to current treatment guidelines.”

In a review of a healthcare registry database, Dr. Thorlund and colleagues found that 50 percent of opioids prescribed in the first year of a knee or hip osteoarthritis diagnosis was “inappropriate” based on recommended treatment guidelines. The study included 399,670 knee osteoarthritis patients and 414,216 hip osteoarthritis patients. Kneed osteoarthritis patients were prescribed codeine (42.5 percent), oxycodone (23.9 percent), tramadol (20.6 percent) or morphine (9.7 percent). Hip osteoarthritis patients were prescribed codeine (39.5 percent), oxycodone (25.4 percent), tramadol (20.9 percent) and morphine (11.5 percent). 

Related Videos
Identifying B-cell Depleting Agents for Lupus Nephritis, with Richard Furie, MD
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
© 2025 MJH Life Sciences

All rights reserved.